{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:19:54Z","timestamp":1794583194545,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health, United States","award":["5R01CA255613"],"award-info":[{"award-number":["5R01CA255613"]}]},{"name":"National Institute of Health, United States","award":["5R01CA255613"],"award-info":[{"award-number":["5R01CA255613"]}]},{"name":"National Institute of Health, United States","award":["5R01CA255613"],"award-info":[{"award-number":["5R01CA255613"]}]},{"name":"National Institute of Health, United States","award":["5R01CA255613"],"award-info":[{"award-number":["5R01CA255613"]}]},{"name":"National Institute of Health, United States","award":["5R01CA255613"],"award-info":[{"award-number":["5R01CA255613"]}]},{"DOI":"10.13039\/100025591","name":"Goldberg Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025591","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Knauss Family Trust, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poly (ADP-Ribose) polymerase inhibitors are approved for treatment of tumors with BRCA1\/2 and other homologous recombination repair (HRR) mutations. However, clinical responses are often not durable and treatment may be detrimental in advanced cancer due to excessive toxicities. Thus we are seeking alternative therapeutics to enhance PARP-directed outcomes. In an effort to expand the clinical use of PARP inhibitors to HRR proficient tumors, several groups have tested combinations of DNA methyltransferase inhibitors and PARP inhibitors. While this approach attenuated tumor cell proliferation in preclinical studies, subsequent clinical trials revealed little benefit. We hypothesized that benefit for this drug combination would only be specific to HRR deficient tumors, due to their inability to enact high fidelity DNA repair with subsequent cell death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated hypomorphic BRCA1 and BRCA2 variants of the HRR proficient triple negative breast cancer cell line MDA-MB-231. We compared therapeutic response features such as RAD51 focus formation, cell cycle fraction alterations, DNA damage accumulation, colony formation, and cell death of these and other cell lines with and without intrinsic BRCA1\/2 mutations. Results were confirmed in BRCA1\/2 intact and deficient xenografts and PDX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our targeted variants and cells with intrinsic BRCA1\/2 mutations responded to low dose combination therapeutic treatment by G2M stalling, compounded DNA damage, severely attenuated colony formation, and importantly, increased cell death. In contrast, the parental MDA-MB-231 cells and other HRR proficient cell lines produced smaller cell populations with short term treatment, but with much less cumulative DNA damage, and minimal cell death. In animal studies, our BRCA-engineered hypomorphs and several independent PDX models with clinically relevant BRCA mutations were acutely more vulnerable to this drug combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We conclude that low dose DNA methyltransferase inhibition can cooperate with low dose PARP inhibition to increase DNA damage predominantly in cells with HRR deficiencies, ultimately producing more cell death than in HRR proficient tumors. We predict that clinical benefit will more likely be apparent in patients with DNA repair defective tumors and are focusing clinical exploration of this drug combination in these patients, with the goals of enhancing tumor cell death at minimal toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-024-01954-y","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T07:14:00Z","timestamp":1737011640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors"],"prefix":"10.1186","volume":"27","author":[{"given":"Romain","family":"Pacaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibapriya","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luika A.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"5","key":"1954_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351.","journal-title":"N Engl J Med"},{"issue":"23","key":"1954_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"10","key":"1954_CR3","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1245\/s10434-013-3205-1","volume":"20","author":"R Greenup","year":"2013","unstructured":"Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1954_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/medicina57090905","volume":"57","author":"YC Lee","year":"2021","unstructured":"Lee YC, Lee YL, Li CY. BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies. Medicina. 2021;57(9):905.","journal-title":"Medicina"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","volume":"2","author":"CC Chen","year":"2018","unstructured":"Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer. Annu Rev Cancer Biol. 2018;2:313\u201336.","journal-title":"Annu Rev Cancer Biol"},{"issue":"7","key":"1954_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0968-0004(98)01232-8","volume":"23","author":"P Baumann","year":"1998","unstructured":"Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23(7):247\u201351.","journal-title":"Trends Biochem Sci"},{"issue":"24","key":"1954_CR7","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","volume":"16","author":"M Graeser","year":"2010","unstructured":"Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(24):6159\u201368.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6330","key":"1954_CR8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"3","key":"1954_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255\u201382.","journal-title":"Target Oncol"},{"issue":"2","key":"1954_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The importance of Poly(ADP-ribose) polymerase as a sensor of unligated okazaki fragments during DNA replication. Mol Cell. 2018;71(2):319\u201331.","journal-title":"Mol Cell"},{"issue":"10","key":"1954_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1954_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8: 564601.","journal-title":"Front Cell Dev Biol"},{"issue":"18","key":"1954_CR13","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","volume":"19","author":"Y Shen","year":"2013","unstructured":"Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(18):5003\u201315.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"21","key":"1954_CR14","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Can Res. 2012;72(21):5588\u201399.","journal-title":"Can Res"},{"issue":"21","key":"1954_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"1954_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13072-021-00400-z","volume":"14","author":"XG Pappalardo","year":"2021","unstructured":"Pappalardo XG, Barra V. Losing DNA methylation at repetitive elements and breaking bad. Epigenetics Chromatin. 2021;14(1):25.","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"1954_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/hmg\/ddq451","volume":"20","author":"K Ha","year":"2011","unstructured":"Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, et al. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet. 2011;20(1):126\u201340.","journal-title":"Hum Mol Genet"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","volume":"754","author":"B Jin","year":"2013","unstructured":"Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3\u201329.","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"1954_CR19","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/cncr.23463","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112(11):2341\u201351.","journal-title":"Cancer"},{"issue":"10","key":"1954_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630\u201341.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"1954_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8\u201313.","journal-title":"Int J Cancer"},{"issue":"4","key":"1954_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents: a potential therapy for cancer. Cancer Cell. 2016;30(4):637\u201350.","journal-title":"Cancer Cell"},{"issue":"13","key":"1954_CR23","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","volume":"24","author":"N Pulliam","year":"2018","unstructured":"Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, et al. An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(13):3163\u201375.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"45","key":"1954_CR24","doi-asserted-by":"publisher","first-page":"22609","DOI":"10.1073\/pnas.1903765116","volume":"116","author":"R Abbotts","year":"2019","unstructured":"Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, et al. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation. Proc Natl Acad Sci USA. 2019;116(45):22609\u201318.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1954_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","volume":"28","author":"MR Baer","year":"2022","unstructured":"Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(7):1313\u201322.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"W1","key":"1954_CR26","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucl Acids Res. 2020;48(W1):W488\u201393.","journal-title":"Nucl Acids Res"},{"issue":"1","key":"1954_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling DR, Swain-Bowden MJ, Lucas AM, Carpenter AE, Cimini BA, Goodman A. Cell Profiler 4: improvements in speed, utility and usability. BMC Bioinform. 2021;22(1):433.","journal-title":"BMC Bioinform"},{"issue":"11","key":"1954_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"issue":"9","key":"1954_CR29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.molp.2015.05.009","volume":"8","author":"W Liu","year":"2015","unstructured":"Liu W, Xie X, Ma X, Li J, Chen J, Liu YG. DSDecode: a web-based tool for decoding of sequencing chromatograms for genotyping of targeted mutations. Mol Plant. 2015;8(9):1431\u20133.","journal-title":"Mol Plant"},{"issue":"1","key":"1954_CR30","doi-asserted-by":"publisher","first-page":"e201204005","DOI":"10.5936\/csbj.201204005","volume":"1","author":"SL Clark","year":"2012","unstructured":"Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J. 2012;1(1):e201204005.","journal-title":"Comput Struct Biotechnol J"},{"issue":"D1","key":"1954_CR31","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1954_CR32","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/genes12071034","volume":"12","author":"PR Andreassen","year":"2021","unstructured":"Andreassen PR, Seo J, Wiek C, Hanenberg H. Understanding BRCA2 function as a tumor suppressor based on domain-specific activities in DNA damage responses. Genes (Basel). 2021;12(7):1034.","journal-title":"Genes (Basel)."},{"issue":"1","key":"1954_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/0008-5472.CAN-05-2853","volume":"66","author":"F Elstrodt","year":"2006","unstructured":"Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Can Res. 2006;66(1):41\u20135.","journal-title":"Can Res"},{"issue":"1","key":"1954_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1954_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27\u201331.","journal-title":"J Basic Clin Pharm"},{"issue":"18","key":"1954_CR36","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.1074\/jbc.C000881200","volume":"276","author":"R Hashizume","year":"2001","unstructured":"Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem. 2001;276(18):14537\u201340.","journal-title":"J Biol Chem"},{"issue":"6","key":"1954_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","volume":"20","author":"R Drost","year":"2011","unstructured":"Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011;20(6):797\u2013809.","journal-title":"Cancer Cell"},{"issue":"8","key":"1954_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/sj.onc.1206263","volume":"22","author":"M Tarsounas","year":"2003","unstructured":"Tarsounas M, Davies D, West SC. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene. 2003;22(8):1115\u201323.","journal-title":"Oncogene"},{"issue":"5","key":"1954_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/0092-8674(92)90561-P","volume":"71","author":"H Leonhardt","year":"1992","unstructured":"Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell. 1992;71(5):865\u201373.","journal-title":"Cell"},{"issue":"11","key":"1954_CR40","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1093\/nar\/gkt270","volume":"41","author":"ML Orta","year":"2013","unstructured":"Orta ML, Calderon-Montano JM, Dominguez I, Pastor N, Burgos-Moron E, Lopez-Lazaro M, et al. 5-Aza-2\u2019-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair. Nucleic Acids Res. 2013;41(11):5827\u201336.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1954_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/83730","volume":"27","author":"L Jackson-Grusby","year":"2001","unstructured":"Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet. 2001;27(1):31\u20139.","journal-title":"Nat Genet"},{"issue":"16","key":"1954_CR42","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1093\/hmg\/ddr236","volume":"20","author":"JE Loughery","year":"2011","unstructured":"Loughery JE, Dunne PD, O\u2019Neill KM, Meehan RR, McDaid JR, Walsh CP. DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. Hum Mol Genet. 2011;20(16):3241\u201355.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1954_CR43","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.24200","volume":"115","author":"MJ Hall","year":"2009","unstructured":"Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222\u201333.","journal-title":"Cancer"},{"issue":"5","key":"1954_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ijc.20162","volume":"110","author":"B Gorski","year":"2004","unstructured":"Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004;110(5):683\u20136.","journal-title":"Int J Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01954-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T07:52:45Z","timestamp":1737013965000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01954-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01954-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were conducted under the UCSF institutional animal care and use committee approval (AN180895-03C). Experiments were performed in accordance with the approved protocol and other relevant guidelines and regulations. Studies\u00a0were stopped when control animal tumor volumes became\u2009>\u20091500 mm\n                      3\n                      per institutional guidelines. This tumor size was not exceeded during the course of our experiments. Source data for figures describing tumor growth are available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}